Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.55 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | BUB1 | O43683 | 1/20 | 0.46 |
| ▸ | STK10 | O94804 | 1/20 | 0.46 |
| ▸ | CARS1 | P49589 | 1/20 | 0.46 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.46 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.46 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20826081 | 1.00 | EGFR (0.55) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL1012990 | 0.95 | EGFR (0.52) | EGFR | |
| SCHEMBL31004058 | 0.95 | EGFR (0.52) | EGFR | |
| SCHEMBL20865361 | 0.88 | EGFR (0.48) | EGFR | |
| SCHEMBL367950 | 0.84 | PDE5A (0.48) | EGFR | |
| SCHEMBL29589537 | 0.84 | PDE5A (0.48) | EGFR | |
| Hydrochloric Acid SCHEMBL8808443 | 0.83 | PDE5A (0.47) | EGFR | |
| SCHEMBL24332725 | 0.80 | EGFR (0.49) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL16253984 | 0.80 | EGFR (0.49) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL15996428 | 0.75 | EGFR (0.49) | EGFRGAKRIPK2BUB1STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021017996-A1 | PHENYLPIPERAZINE QUINAZOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 暨南大学 | 2021-02-04 | — | — | WO | disclosed |
| EP-2593462-B1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS C-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| US-9359370-B2 | Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof | BETA PHARMA, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359370-B2 | Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof | BETA PHARMA, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| EP-2392576-B1 | ICOTINIB HYDROCHLORIDE, SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF | BETA PHARMA INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9242991-B2 | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| US-20140343082-A1 | ICOTINIB HYDROCHLORIDE, SYNTHESIS, CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BETA PHARMA, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140343082-A1 | ICOTINIB HYDROCHLORIDE, SYNTHESIS, CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BETA PHARMA, INC. | 2014-11-20 | — | — | US | disclosed |
| US-8822482-B2 | Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof | BETA PHARMA, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822482-B2 | Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof | BETA PHARMA, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| EP-2593462-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | Zhejiang Beta Pharma Inc. (CN) | 2013-05-22 | — | — | EP | disclosed |
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2013-05-16 | — | — | US | disclosed |
| WO-2012006960-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | ZHEJIANG BETA PHARMA INC. (CN) | 2012-01-19 | — | — | WO | disclosed |
| EP-2392576-A1 | ICOTINIB HYDROCHLORIDE, SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF | Beta Pharma, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110182882-A1 | Icotinib Hydrochloride, Synthesis, Crystalline Forms, Pharmaceutical Compositions, and Uses Thereof | BETA PHARMA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182882-A1 | Icotinib Hydrochloride, Synthesis, Crystalline Forms, Pharmaceutical Compositions, and Uses Thereof | BETA PHARMA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343082-A1 | ICOTINIB HYDROCHLORIDE, SYNTHESIS, CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | ABL1, EGFR, ERBB2 | EGFR 2/4885GAK 168/4885RIPK2 879/4885 |
| US-20110182882-A1 | Icotinib Hydrochloride, Synthesis, Crystalline Forms, Pharmaceutical Compositions, and Uses Thereof | ABL1, EGFR, ERBB2 | EGFR 2/4885GAK 168/4885RIPK2 879/4885 |
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | MET, RET, ABL1 | EGFR 30/4885GAK 404/4885RIPK2 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.